Could old drugs beat rare cancers? new trial aims to find out
NCT ID NCT05722886
First seen Jun 25, 2026 · Last updated Jul 02, 2026 · Updated 3 times
Summary
The DETERMINE trial is testing whether drugs already approved for some cancers can help people with rare cancers or common cancers that have rare genetic mutations. It will enroll 825 adults, teenagers, and children whose cancers have specific DNA changes. The goal is to find new uses for existing targeted therapies and make them available through the NHS if they work.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- targeted therapies (e.g., alectinib, atezolizumab)
- What this could lead to
- If successful, this could expand treatment options for people with rare cancers or uncommon genetic mutations, potentially making existing drugs available to new patient groups.
- What could go wrong
- This is an early-stage platform trial testing many drugs across many cancer types. Not all drugs will work for every mutation, and results may take years to confirm. Side effects from the drugs are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HAEMATOLOGICAL MALIGNANCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Addenbrooke's Hospital
RECRUITINGCambridge, CB2 OQQ, United Kingdom
-
Alder Hey Hospital
RECRUITINGLiverpool, L14 5AB, United Kingdom
-
Belfast City Hospital
RECRUITINGBelfast, BT9 7AB, United Kingdom
-
Birmingham Children's Hospital
NOT_YET_RECRUITINGBirmingham, B4 6NH, United Kingdom
-
Bristol Haematology and Oncology Centre
RECRUITINGBristol, BS2 8ED, United Kingdom
-
Bristol Royal Hospital for Children
RECRUITINGBristol, BS2 8BJ, United Kingdom
-
Cardiff Children's Hospital
RECRUITINGCardiff, CF14 4XW, United Kingdom
-
Churchill Hospital
RECRUITINGOxford, OX3 7LE, United Kingdom
-
Clatterbridge Cancer Centre
RECRUITINGMetropolitan Borough of Wirral, CH63 4JY, United Kingdom
-
Freeman Hospital
RECRUITINGNewcastle, NE7 7DN, United Kingdom
-
Great North Children's Hospital
RECRUITINGNewcastle, NE1 4LP, United Kingdom
-
Great Ormond Street Hospital
RECRUITINGLondon, WC1N 3JH, United Kingdom
-
Guy's Hospital
RECRUITINGLondon, SE1 9RT, United Kingdom
-
John Radcliffe Hospital
RECRUITINGOxford, OX3 9DU, United Kingdom
-
Leicester Royal Infirmary
RECRUITINGLeicester, LE1 5WW, United Kingdom
-
Royal Hospital for Children Glasgow
RECRUITINGGlasgow, G51 4TF, United Kingdom
-
Royal Manchester Children's Hospital
RECRUITINGManchester, M13 9WL, United Kingdom
-
Sheffield's Children's Hospital
RECRUITINGSheffield, S10 2TH, United Kingdom
-
Southampton General Hospital
RECRUITINGSouthampton, SO16 6YD, United Kingdom
-
The Beatson Hospital
RECRUITINGGlasgow, G12 OYN, United Kingdom
-
The Christie Hospital
RECRUITINGManchester, M20 4BX, United Kingdom
-
The Royal Marsden Hospital
RECRUITINGSutton, SM2 5PT, United Kingdom
-
University College London Hospital
RECRUITINGLondon, NW1 2BU, United Kingdom
-
University Hospital Birmingham
RECRUITINGBirmingham, B15 2TT, United Kingdom
-
Velindre Cancer Centre
RECRUITINGCardiff, CF14 2TL, United Kingdom
-
Western General Hospital
RECRUITINGEdinburgh, EH4 2XU, United Kingdom
-
Weston Park Hospital
RECRUITINGSheffield, S10 2SJ, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Cancer care goes home: study tests nurse visits to cut hospital trips
- Blood cancer chemo and adrenal risk study pulled before start
- Can a simple drink help blood cancer patients recover from stem cell transplants?
- Are CLL patients getting fair referrals? new study investigates
- Could existing cancer drugs tackle rare tumors? new trial aims to find out
- Antibody clues after stem cell transplants could prevent rejection